EUCTR2022-001091-34-SI进行中（未招募）1 期
A double blind, randomized, placebo-controlled trial evaluatingthe efficacy and safety of BI 1015550 over at least 52 weeks inpatients with Idiopathic Pulmonary Fibrosis (IPF) - PDE4 Phase III trial in IPF (Fibroneer- IPF)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 963
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients =40 years old at the time of signed consent
- •IPF diagnosis based on 2022 ATS/ERS/JRS/ALAT Guidelines
- •FVC =45% of predicted normal
- •DLCO =25% and <90% predicted of normal
- •On stable treatment with nintedanib or pirfenidone for at least
- •12 weeks or not on treatment with either nintedanib or
- •pirfenidone for at least 8 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 337
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 626
排除标准
- •Relevant airways obstruction (prebronchodilator FEV1/FVC
- •Acute IPF exacerbation within 3 months and/or during the
- •screening period
- •Treated with immunomodulatory medications (other than oral
- •corticosteroids) or prednisone >15 mg/day or equivalent for
- •respiratory or pulmonary reasons
- •Active, unstable or uncontrolled vasculitis within 8 weeks
- •Any suicidal behaviour in the past 2 years
- •Any suicidal ideation of type 4 or 5 on the C-SSRS in the past 3 months
研究者
相似试验
招募中
1 期
A study to find out whether BI 1015550 improves lung functionin people with Idiopathic Pulmonary Fibrosis (IPF)EUCTR2022-001091-34-EEBoehringer Ingelheim France963
进行中（未招募）
1 期
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)EUCTR2022-001134-11-GRBoehringer Ingelheim B.V1,041
招募中
1 期
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)MedDRA version: 23.1Level: LLTClassification code 10084309Term: Progressive fibrosing interstitial lung diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-001134-11-ATBoehringer Ingelheim RCV GmbH & Co KG1,041
进行中（未招募）
1 期
Efficacy and safety of nintedanib in patients with PF-ILDEUCTR2015-003360-37-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.1,010
招募中
1 期
A study to find out whether BI 1015550 improves lung function in people with Idiopathic Pulmonary Fibrosis (IPF)EUCTR2022-001091-34-DEBoehringer Ingelheim Pharma GmbH & Co. KG963